Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,107Revenue $M16,671Net Margin (%)14.8Z-Score3.2
Enterprise Value $M42,737EPS $4.6Operating Margin %17.2F-Score6
P/E(ttm))14.9Cash Flow Per Share $5.6Pre-tax Margin (%)15.1Higher ROA y-yY
Price/Book4.610-y EBITDA Growth Rate %10.9Quick Ratio1.1Cash flow > EarningsY
Price/Sales2.25-y EBITDA Growth Rate %5.5Current Ratio1.7Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %3.7ROA % (ttm)9.8Higher Current Ratio y-yN
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)29.5Less Shares Outstanding y-yY
Payout Ratio %58.0Shares Outstanding M543ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXRichard Pzena 2014-12-31 Buy 1.5%$67.24 - $74.7
($71.71)
$ 68.39-5%New holding3,944,140
BAXJean-Marie Eveillard 2014-12-31 Reduce-0.06%$67.24 - $74.7
($71.71)
$ 68.39-5%Reduce -32.14%676,637
BAXMario Gabelli 2014-12-31 Reduce-0.02%$67.24 - $74.7
($71.71)
$ 68.39-5%Reduce -23.14%172,900
BAXBill Nygren 2014-12-31 Sold Out -0.75%$67.24 - $74.7
($71.74)
$ 68.39-5%Sold Out0
BAXDavid Dreman 2014-09-30 Buy 0.02%$71.28 - $77
($74.81)
$ 68.39-9%New holding3,397
BAXRay Dalio 2014-09-30 Add0.01%$71.28 - $77
($74.81)
$ 68.39-9%Add 220.37%18,463
BAXRobert Olstein 2014-09-30 Sold Out -0.59%$71.28 - $77
($74.81)
$ 68.39-9%Sold Out0
BAXScott Black 2014-06-30 Reduce-0.43%$71.98 - $75.45
($73.67)
$ 68.39-8%Reduce -30.98%123,976
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 68.39-8%Add 90872.40%1,000,696
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 68.39-8%New holding37,150
BAXRay Dalio 2014-06-30 Reduce-0.03%$71.98 - $75.45
($73.67)
$ 68.39-8%Reduce -90.74%5,763
BAXJohn Hussman 2014-06-30 Reduce-0.02%$71.98 - $75.45
($73.67)
$ 68.39-8%Reduce -50.00%3,725
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 68.39-8%Sold Out0
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 68.39-8%Sold Out0
BAXJohn Hussman 2014-03-31 Reduce-0.49%$66.49 - $72.85
($68.75)
$ 68.39-1%Reduce -93.07%7,450
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 68.39-1%Reduce -77.96%531,100
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 68.39-1%New holding204,560
BAXScott Black 2014-03-31 Add0.17%$66.49 - $72.85
($68.75)
$ 68.39-1%Add 13.41%179,629
BAXRay Dalio 2014-03-31 Reduce-0.07%$66.49 - $72.85
($68.77)
$ 68.39-1%Reduce -67.00%62,263
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 68.39-1%New holding2,453
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HELLMAN PETER SDirector 2015-02-06Sell4,830$71.32-4.64view
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-9.2view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-11.65view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-11.47view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-10.51view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.41-8.6view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-9.66view
STROUCKEN ALBERT P LDirector 2014-04-24Buy696$67.520.73view
STORM KEES JDirector 2014-04-23Sell5,760$72.45-6.13view
Devitt Blake EDirector 2014-04-21Sell4,334$73.12-6.99view

Press Releases about BAX :

    Quarterly/Annual Reports about BAX:

    News about BAX:

    Articles On GuruFocus.com
    Live Off Your Monthly Dividend Portfolio Mar 19 2015 
    Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
    To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
    Best Stock Pick For Long Term Investors Feb 10 2015 
    Richard Pzena's New Buys Feb 09 2015 
    Richard Pzena's 5 New Q4 Stock Buys Feb 07 2015 
    Expectations, Price, and Fundamentals (Or Congressional Questions Gone Awry) Jan 23 2015 
    Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
    I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
    Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 


    More From Other Websites
    Baxter International Inc. -- Moody's puts Baxter's ratings (A3/P-2) on review for downgrade as... Mar 26 2015
    Final Glance: Pharmaceuticals companies Mar 26 2015
    Final Glance: Pharmaceuticals companies Mar 26 2015
    Final Glance: Medical Devices companies Mar 26 2015
    Final Glance: Medical Devices companies Mar 26 2015
    Midday Glance: Pharmaceuticals companies Mar 26 2015
    Midday Glance: Medical Devices companies Mar 26 2015
    Midday Glance: Medical Devices companies Mar 26 2015
    Midday Glance: Pharmaceuticals companies Mar 26 2015
    Early Glance: Medical Devices companies Mar 26 2015
    Early Glance: Pharmaceuticals companies Mar 26 2015
    Early Glance: Pharmaceuticals companies Mar 26 2015
    Early Glance: Medical Devices companies Mar 26 2015
    BAXTER INTERNATIONAL INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Mar 25 2015
    State gives $19M in tax breaks to life science firms who will add 1,075 new jobs Mar 18 2015
    Nektar's Breast Cancer Candidate Fails in BEACON Study - Analyst Blog Mar 18 2015
    S&P 500 companies with the largest off-balance sheet tax liabilities Mar 17 2015
    Baxter's BAX 817 Tests Positive for Hemophilia Treatment - Analyst Blog Mar 17 2015
    Baxter BioScience Announces Positive Phase III Results for BAX 817, Investigational Recombinant... Mar 15 2015
    Baxter BioScience Announces Positive Phase III Results for BAX 817, Investigational Recombinant... Mar 13 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Sww
    ReplySww - 8 months ago
    Bax medical devices revenue ~9b, bio science ~7b
    using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

    72 * (1 + 16/39) = 99

    72 is current stock price, with an upside of around 35%

    so my guess is BAX may be able to sell for around 90 after spin-off.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK